Tilray Brands posts record fiscal 2026 revenue as GAAP losses and dilution check the rally
Cannabis equities have struggled to translate legalization momentum into sustained price gains, and Tilray Brands (NASDAQ: TLRY) is running that playbook in real time. The Canada-based company posted record fiscal 2026 revenue of…
Key takeaways
- Tilray Brands posted record fiscal 2026 revenue of approximately $915 million, up 11% year on year, in financials released July 28.
- Adjusted EBITDA rose 11% to $61.1 million and adjusted net income nearly doubled to $12.2 million, but on a GAAP basis Tilray had net losses of $49.6 million, or negative 43 cents per share.
- Tilray's debt is now effectively zero, achieved partly through dilutive debt-for-equity swaps that pressure per-share metrics.
- Cannabis now accounts for just 29% of Tilray's overall sales, with the rest in alcoholic beverages and pharmaceutical distribution.
- For fiscal 2027, management expects adjusted EBITDA of $68 million to $75 million, without specifying whether that converts to positive GAAP earnings.
Cannabis equities have struggled to translate legalization momentum into sustained price gains, and Tilray Brands (NASDAQ: TLRY) is running that playbook in real time. The Canada-based company posted record fiscal 2026 revenue of approximately $915 million, a gain of 11% year on year, when it released quarterly financials on July 28. A modest post-earnings rally followed. It has since faded.
The headline numbers are, on their face, constructive. Adjusted EBITDA rose 11% to $61.1 million. Adjusted net income nearly doubled, from $6.5 million to $12.2 million. Against those gains, adjusted earnings still came in below sell-side forecasts, and management's characterization of the period as record revenue and record adjusted EBITDA did not change the shortfall. On a GAAP basis the picture is harder: net losses attributable to Tilray shareholders totaled $49.6 million, or negative 43 cents per share.
Management pointed to a debt position now effectively at zero as a mark of financial discipline, but the route there runs through debt-for-equity swaps, a dilutive mechanism that compounds pressure on per-share metrics regardless of top-line direction. The company has a standing target of $1 billion in annual revenue; reaching that figure while simultaneously reversing share dilution and clearing GAAP losses is the harder version of the problem.
Against the backdrop of continuing U.S. federal marijuana rescheduling efforts, the sector-wide assumption is that cannabis-exposed companies stand to benefit materially from a legalization event. The read-through for Tilray is more complicated than the ticker implies. Cannabis now accounts for just 29% of overall sales, with the balance spread across alcoholic beverages and pharmaceutical distribution, segments that carry little of the regulatory upside the market prices into cannabis names. Tilray has, in effect, diversified away from the very catalyst the market is using to value it. A federal rescheduling event would move the needle considerably less than the headline stock narrative implies.
On balance, the cross-border legalization story and Tilray's actual revenue composition are running at different speeds. The market is pricing a cannabis company; the income statement increasingly reflects a beverage and distribution business with a cannabis segment attached. For fiscal 2027, management expects adjusted EBITDA of $68 million to $75 million. Whether that converts to positive GAAP earnings was left unspecified.
Related reading
Source · 來源